Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Published October 16, 2023
Citation Information: J Clin Invest. 2023;133(20):e166494. https://doi.org/10.1172/JCI166494.
View: Text | PDF
Research Article Oncology

Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

  • Text
  • PDF
Abstract

Carcinogen exposure is strongly associated with enhanced cancer immunogenicity. Increased tumor mutational burden and resulting neoantigen generation have been proposed to link carcinogen exposure and cancer immunogenicity. However, the neoantigen-independent immunological impact of carcinogen exposure on cancer is unknown. Here, we demonstrate that chemical carcinogen-exposed cancer cells fail to establish an immunosuppressive tumor microenvironment (TME), resulting in their T cell–mediated rejection in vivo. A chemical carcinogen-treated breast cancer cell clone that lacked any additional coding region mutations (i.e., neoantigen) was rejected in mice in a T cell–dependent manner. Strikingly, the coinjection of carcinogen- and control-treated cancer cells prevented this rejection, suggesting that the loss of immunosuppressive TME was the dominant cause of rejection. Reduced M-CSF expression by carcinogen-treated cancer cells significantly suppressed tumor-associated macrophages (TAMs) and resulted in the loss of an immunosuppressive TME. Single-cell analysis of human lung cancers revealed a significant reduction in the immunosuppressive TAMs in former smokers compared with individuals who had never smoked. These findings demonstrate that carcinogen exposure impairs the development of an immunosuppressive TME and indicate a novel link between carcinogens and cancer immunogenicity.

Authors

Mei Huang, Yun Xia, Kaiwen Li, Feng Shao, Zhaoyi Feng, Tiancheng Li, Marjan Azin, Shadmehr Demehri

×

Figure 4

Carcinogen-induced TAMs have antitumor properties.

Options: View larger image (or click on image) Download as PowerPoint
Carcinogen-induced TAMs have antitumor properties.
(A) Representative fl...
(A) Representative flow cytometric analysis of DMBA3-4 and DMSO3-1 TAMs in the tumors from Rag1KO mice. Numbers on the dot plots represent the percent cells within each gate. (B) F4/80+ leukocyte (TAM) frequencies in DMBA3-4 and DMSO3-1 tumors (n = 6 per group). (C) CD11b+ F4/80+ leukocyte (TAM) frequencies in DMBA3-4 and DMSO3-1 tumors (n = 6 per group). (D) Mean fluorescence intensity (MFI) of CD11b expression on DMBA3-4 and DMSO3-1 TAMs (n = 6 per group). (E) Representative immunofluorescence images of CD11b- and F4/80-stained DMBA3-4 and DMSO3-1 tumors from Rag1KO mice. Scale bar: 100 μm. (F) CD11bhi F4/80+ TAM counts in DMBA3-4 and DMSO3-1 tumors. TAMs were quantified in 4 randomly selected high-power field (hpf) images per sample (n = 6 per group). Each dot represents a hpf image. (G and H) MFI of (G) arginase 1 (Arg1) and (H) CD86 expression in DMBA3-4 and DMSO3-1 TAMs (n = 6 per group). (I) MHCII expression on CD11b+ F4/80+ TAMs. Numbers on the flow histograms represent the percent MHCIIhi TAMs. (J) MHCIIhi TAM frequencies in DMBA3-4 and DMSO3-1 tumors from Rag1KO mice (n = 6 per group). (K) DMSO3-1 tumor growth in WT C57BL/6 mice treated with clodronate liposome versus control liposome. Liposome i.p. injections were performed on days 1, 3, 10, and 17 after tumor inoculation (red arrows, n = 6 per group). (L) Differentially expressed (DE) genes in DMBA3-4 versus DMSO3-1 TAMs from Rag1KO mice. The significantly upregulated and downregulated genes are indicated with red and blue dots, respectively (n = 6 per group). Unpaired t test (B–D, F–H, and J) and 2-way ANOVA (K), bar graphs show mean + SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts